CHS / AHCDC / CSL Behring Hemostasis Fellowship Program
CHS/AHCDC/CSL Behring Hemostasis Fellowship Program, was a fellowship
in Congenital and Acquired Bleeding Disorders, that was established in
the fall of 2001 as a result of a collaborative effort among Novo
Nordisk Canada Inc., the Canadian Hemophilia Society and the Association
of Hemophilia Clinic Directors of Canada. Beginning in 2010, the
Fellowship continued to be made possible thanks to generous financial
support from CSL Behring Canada. The program ended in 2015.
The goal of this program was to provide fellows in Hematology or other relevant fields the opportunity to obtain additional focused clinical or research training relevant to Hemostasis so that they may improve the care, the treatment and the quality of the lives of patients with hemophilia and other congenital or acquired bleeding disorders. Consideration was given on an individual basis to candidates from allied health professions undertaking post-graduate studies. The fellowship, valued at $75,000, was used for salary support for outstanding candidates who planned a career in Canada.